CuraSen doses first subjects in phase 1 trial of CST-2032

This article was originally published here

CST-2032 is a brain-permeant, selective adrenoceptor modulator designed to target key receptors in cortical and limbic regions of the brain that are no longer optimally innervated in patients

The post CuraSen doses first subjects in phase 1 trial of CST-2032 appeared first on Pharmaceutical Business review.